Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) fundamentals
Jagsonpal Pharmaceuticals Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as JAGSNPHARM (ISIN INE048B01035). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Jagsonpal Pharmaceuticals Limited does
Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its Gynaecology products include Divatrone, Endoreg, Cystelia-M, Fibristone, Yuliprist, Deereg, and Lycored Softgel. Its Orthopaedics products include JP Tone Up, Metadec 50 Injection, Metadec 25 Injection, Indocap SR, and Indocap, Colla-2. Its other products include Equirex, Doxypal DR-L, JP Tone Syrup, and Lycored Syrup.
Valuation and market data
| Last close | ₹233.84 |
|---|---|
| Market capitalisation | ₹1,567 crore |
| Enterprise value | ₹1,568 crore |
| P/E (TTM) | 0.00 |
| Price to book | 6.53 |
| Price to sales (TTM) | 5.12 |
| Book value per share | ₹35.80 |
| Dividend yield | 277.97% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Mar 01 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹299 crore | ₹58 crore | ₹43 crore | 0.00 |
| Mar 2025 | ₹277 crore | ₹70 crore | ₹55 crore | 8.26 |
| Mar 2024 | ₹218 crore | ₹30 crore | ₹22 crore | 3.40 |
| Mar 2023 | ₹242 crore | ₹35 crore | ₹27 crore | 10.20 |
| Mar 2022 | ₹221 crore | ₹27 crore | ₹19 crore | 7.20 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 69.0% |
|---|---|
| Foreign institutions (FII) | 2.3% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.6% |
| Retail and others | 28.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.